- CareDx (CDNA, Financial) to present 60 abstracts at the 2025 International Society for Heart and Lung Transplantation Meeting.
- The SHORE study highlights the prognostic value of HeartCare in transplant patient management.
- CareDx continues to lead in the adoption of molecular testing solutions in real-world clinical practices.
CareDx, Inc. (CDNA), a prominent precision medicine company, has announced its participation at the 2025 International Society for Heart and Lung Transplantation (ISHLT) Meeting in Boston, Massachusetts. The company will present 60 abstracts, including 19 oral presentations, showcasing advancements in heart and lung transplant patient management.
The presentations will feature clinical evidence for CareDx's HeartCare™, AlloSure® Heart, AlloMap® Heart, AlloSure Lung, and AlloHome™. These sessions will present data generated from studies conducted at 92 transplant centers worldwide, demonstrating the real-world adoption and clinical significance of CareDx's testing solutions.
Highlighted in the presentations is the SHORE study, a large-scale heart transplant study that evaluates over 2,700 patients. The findings reveal that HeartCare is prognostic of long-term graft outcomes, independent of biopsy results, and aids in the management of immunosuppression dosing. Notably, dual-positive HeartCare results predict worse outcomes despite normal biopsy results, while dual-negative results correlate with fewer biopsies and excellent patient outcomes.
In lung transplant management, the AlloSure Lung test has shown efficacy in identifying acute cellular rejection and enabling timely treatment adjustments with the AlloHome remote patient monitoring system.
The meeting will also feature two CareDx-sponsored symposia focusing on the latest molecular management evidence for heart and lung transplant patients, further emphasizing CareDx's leadership in the integration of genomics-based information for transplant care.
